Base de dados : MEDLINE
Pesquisa : D05.750.078.593.450.300.900 [Categoria DeCS]
Referências encontradas : 1396 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 140 ir para página                         

  1 / 1396 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29463190
[Au] Autor:Shirasu H; Ono A; Omae K; Nakashima K; Omori S; Wakuda K; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Takahashi T
[Ad] Endereço:1 Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Nagaizumi-cho, Shizuoka, Japan.
[Ti] Título:CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma.
[So] Source:Tumour Biol;40(2):1010428318760420, 2018 Feb.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CYFRA 21-1 is a prognostic marker for non-small cell lung cancer. The serum CYFRA 21-1 level is also known as an adjunct for the diagnosis of lung squamous cell carcinoma. This study aimed to examine whether CYFRA 21-1 has predictive implications for nivolumab therapy in patients with advanced lung adenocarcinoma. Of the 79 patients who were treated with nivolumab therapy at the Shizuoka Cancer Center between December 2015 and September 2016, we retrospectively reviewed the data of 50 patients. The patient characteristics were as follows: age <70/≥70 years: 43 (86%)/7; male/female: 31 (62.0%)/19; Eastern Cooperative Oncology Group performance status 0-1/2: 43 (86%)/7; smoking status: no/yes: 18 (36%)/32; epidermal growth factor receptor mutation status negative/positive: 36 (72%)/14; CYFRA 21-1 ≥2.2/<2.2 ng/mL: 28 (56%)/22; carcinoembryonic antigen ≥5/<5 ng/mL: 29 (58%)/21; and number of prior regimens 2-3/≥4: 16 (32%)/34. With a median follow-up of 263.5 (range, 64-352) days, the median progression-free survival was 70 days. The clinical variables investigated using univariate analysis were as follows: age (p = 0.423), carcinoembryonic antigen (p = 0.888), epidermal growth factor receptor mutation status (p = 0.105), performance status (p = 0.968), sex (p = 0.210), number of prior regimens (p = 0.146), CYFRA 21-1 (p = 0.026), and smoking status (p = 0.041). A multivariate analysis identified a serum CYFRA 21-1 level ≥2.2 ng/mL as an independent predictor of a favorable outcome (hazard ratio, 0.44; 95% confidence interval, 0.23-0.85; p = 0.015; median progression-free survival, 155 vs 51.5 days). In conclusion, CYFRA 21-1 might be an independent predictor of outcome for patients with advanced lung adenocarcinoma treated with nivolumab.
[Mh] Termos MeSH primário: Adenocarcinoma/tratamento farmacológico
Adenocarcinoma/metabolismo
Anticorpos Monoclonais/uso terapêutico
Antígenos de Neoplasias/metabolismo
Queratina-19/metabolismo
Neoplasias Pulmonares/tratamento farmacológico
Neoplasias Pulmonares/metabolismo
[Mh] Termos MeSH secundário: Adulto
Idoso
Biomarcadores Tumorais/metabolismo
Antígeno Carcinoembrionário/metabolismo
Intervalo Livre de Doença
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Receptor do Fator de Crescimento Epidérmico/metabolismo
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antigens, Neoplasm); 0 (Biomarkers, Tumor); 0 (Carcinoembryonic Antigen); 0 (Keratin-19); 0 (antigen CYFRA21.1); 31YO63LBSN (nivolumab); EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1177/1010428318760420


  2 / 1396 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29247745
[Au] Autor:Jiang ZF; Wang M; Xu JL
[Ad] Endereço:Department of Respiratory Medicine, National Key Clinical Specialist Construction Programs of China, the First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei 230022, Anhui, PR China. Electronic address: 1611601838@qq.com.
[Ti] Título:Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
[So] Source:Life Sci;194:1-6, 2018 Feb 01.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: Thymidine kinase 1 (TK1) is a tumor biomarker in human malignancies. The purpose of this study was to evaluate the diagnostic efficiency of this marker for lung cancer using the combined analysis of carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA21-1), neuron specific enolase (NSE) and TK1. MAIN METHODS: From 2013 to 2014, 147 patients with lung cancer and 228 patients with lung benign diseases who were admitted to our hospital were reviewed. Peripheral blood samples were collected for the detection of TK1, CEA, CYFRA21-1 and NSE. The diagnostic value of each marker was analyzed using receiver operating characteristic (ROC) curves and logistic regression equations. KEY FINDINGS: The serum levels of TK1, CEA, CYFRA21-1 and NSE were significantly higher than those in patients with lung benign diseases (all P<0.05). The TK1 concentration was dependent on TNM stage (P=0.005). The ROC curve analyses showed that the diagnostic value of TK1 combined with CEA, CYFRA21-1 and NSE in lung cancer was significantly higher than that of each biomarker alone (all P<0.0001). In addition, TK1 combined with CEA, CYFRA21-1, or NSE could also improve the diagnosis of the squamous cell carcinoma, adenocarcinoma and small cell lung cancer subtypes, respectively. SIGNIFICANCE: The combined detection of TK1 and the other three markers significantly improved the diagnosis of lung cancer. Furthermore, the detection of TK1 combined with that of CYFRA21-1, CEA or NSE increased the diagnostic value of TK1 for lung squamous cell carcinoma, adenocarcinoma and SCLC, respectively.
[Mh] Termos MeSH primário: Antígenos de Neoplasias/sangue
Antígeno Carcinoembrionário/sangue
Queratina-19/sangue
Neoplasias Pulmonares/sangue
Neoplasias Pulmonares/diagnóstico
Fosfopiruvato Hidratase/sangue
Timidina Quinase/sangue
[Mh] Termos MeSH secundário: Adenocarcinoma/sangue
Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais/sangue
Carcinoma Pulmonar de Células não Pequenas/sangue
Carcinoma de Células Escamosas/sangue
Feminino
Seres Humanos
Masculino
Meia-Idade
Curva ROC
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Biomarkers, Tumor); 0 (Carcinoembryonic Antigen); 0 (Keratin-19); 0 (antigen CYFRA21.1); EC 2.7.1.21 (Thymidine Kinase); EC 2.7.1.21 (thymidine kinase 1); EC 4.2.1.11 (Phosphopyruvate Hydratase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE


  3 / 1396 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245248
[Au] Autor:Wang H; Yang X
[Ad] Endereço:aDepartment of Pathology, Weihai Maternal and Child Health HospitalbDepartment of Dermatology, Weihai Municipal Hospital, Weihai, China.
[Ti] Título:Association between serum cytokines and progression of breast cancer in Chinese population.
[So] Source:Medicine (Baltimore);96(49):e8840, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to investigate the roles of serum interleukin-6 (IL-6), IL-8, IL-10, squamous cell cancer antigen (SCC-Ag), and cytokeratin 21-1 fragment (CYFRA 21-1) in the metastasis and prognosis of breast cancer.A total of 534 breast cancer patients admitted to our department between January 2011 and December 2014 were enrolled in this study. Besides, 452 matched healthy individuals received physical examination at the same period served as the normal control. Serum IL-6, IL-8, IL-10, and tumor necrosis factor-α (TNF-α) were determined using an immunoradiometric assay. SCC-Ag level was evaluated using chemiluminescent microparticle immunoassay. CYFRA 21-1 was determined using the chemiluminescence assay.Compared with the control group, a significant increase was noticed in the serum IL-6, IL-8, and IL-10 in breast cancer patients, especially those with severe conditions (P < .01). Serum IL-6, IL-8, and IL-10 showed a significant increase in the patients with severe breast cancer compared with those with mild conditions (P < .05). For the patients with response after radiotherapy, the serum IL-6, IL-8, and IL-10 were significantly decreased compared with the baseline levels (P < .05). The median survival duration for the patients of SCC-Ag negative patients was 25 months, while that for the SCC-Ag positive group was 16 months. Significant difference was noticed in the survival of SCC-Ag negative group compared with that of SCC-Ag positive group (P < .05).Serum IL-6, IL-8, IL-10, SCC-Ag, and CYFRA 21-1 were considered as potential markers in the metastasis and prognosis of breast cancer.
[Mh] Termos MeSH primário: Antígenos de Neoplasias/sangue
Biomarcadores Tumorais/sangue
Neoplasias da Mama/sangue
Citocinas/sangue
Progressão da Doença
Queratina-19/sangue
Serpinas/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Estudos de Casos e Controles
China
Feminino
Seres Humanos
Interleucina-10/sangue
Interleucina-6/sangue
Interleucina-8/sangue
Meia-Idade
Prognóstico
Fator de Necrose Tumoral alfa/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Biomarkers, Tumor); 0 (Cytokines); 0 (IL10 protein, human); 0 (IL6 protein, human); 0 (Interleukin-6); 0 (Interleukin-8); 0 (Keratin-19); 0 (Serpins); 0 (Tumor Necrosis Factor-alpha); 0 (antigen CYFRA21.1); 0 (squamous cell carcinoma-related antigen); 130068-27-8 (Interleukin-10)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171222
[Lr] Data última revisão:
171222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008840


  4 / 1396 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28982900
[Au] Autor:Takeuchi A; Oguri T; Sone K; Ito K; Kitamura Y; Inoue Y; Asano T; Fukuda S; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
[Ad] Endereço:Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
[Ti] Título:Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
[So] Source:Anticancer Res;37(10):5771-5776, 2017 10.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Tyrosine kinase inhibitors (TKIs) directed against epidermal growth factor receptor (EGFR) are important in the treatment of non-small cell lung cancer (NSCLC), especially those harboring EGFR mutations. But little is known regarding the clinical value of serum tumor marker levels measured prior to treatment. PATIENTS AND METHODS: We retrospectively reviewed 95 patients with advanced NSCLC treated with EGFR-TKIs, and inspected the relationship between serum tumor marker levels and clinical outcome. RESULTS: Forty-three patients with an elevated serum level of cytokeratin 19 fragment (CYFRA 21-1) had shorter progression-free (PFS) and overall (OS) survival than 52 patients with normal serum CYFRA 21-1 levels (99 vs. 123.5 days p=0.011; and 385 vs. 607 days, respectively, p=0.001). Regardless of EGFR mutation status, patients had shorter progression-free survival when serum CYFRA 21-1 was elevated. CONCLUSION: Serum CYFRA 21-1 level may be a predictive factor for patients with NSCLC treated with EGFR-TKIs, regardless of EGFR mutation status.
[Mh] Termos MeSH primário: Antígenos de Neoplasias/sangue
Antineoplásicos/uso terapêutico
Biomarcadores Tumorais
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Queratina-19/sangue
Neoplasias Pulmonares/tratamento farmacológico
Inibidores de Proteínas Quinases/uso terapêutico
Receptor do Fator de Crescimento Epidérmico/antagonistas & inibidores
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/efeitos adversos
Biomarcadores Tumorais/antagonistas & inibidores
Biomarcadores Tumorais/sangue
Biomarcadores Tumorais/genética
Carcinoma Pulmonar de Células não Pequenas/enzimologia
Carcinoma Pulmonar de Células não Pequenas/patologia
Intervalo Livre de Doença
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Neoplasias Pulmonares/sangue
Neoplasias Pulmonares/enzimologia
Neoplasias Pulmonares/patologia
Masculino
Meia-Idade
Terapia de Alvo Molecular
Mutação
Valor Preditivo dos Testes
Modelos de Riscos Proporcionais
Inibidores de Proteínas Quinases/efeitos adversos
Receptor do Fator de Crescimento Epidérmico/genética
Estudos Retrospectivos
Fatores de Risco
Transdução de Sinais/efeitos dos fármacos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); 0 (Keratin-19); 0 (Protein Kinase Inhibitors); 0 (antigen CYFRA21.1); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  5 / 1396 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28968445
[Au] Autor:Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
[Ad] Endereço:Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.
[Ti] Título:Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
[So] Source:PLoS One;12(10):e0185850, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this study, we aimed to examine the clinical value of the pleural effusion (PE) biomarkers, soluble mesothelin-related peptide (SMRP), cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA), and the utility of combining chest computed tomography (CT) findings with these biomarkers, in diagnosing malignant pleural mesothelioma (MPM). We conducted a retrospective cohort study in a single center. Consecutive patients with undiagnosed pleural effusions who underwent PE analysis between September 2014 and August 2016 were reviewed. This study included 240 patients (32 with MPM and 208 non-MPM). SMRP and the CYFRA 21-1/CEA ratio had a sensitivity and specificity for diagnosing MPM of 56.3% and 86.5%, and 87.5% and 74.0%, respectively. Using receiver operating characteristics (ROC) curve analysis of the ability of these markers to distinguish MPM from all other PE causes, the area under the ROC curve (AUC) for SMRP and the CYFRA 21-1/CEA ratio was 0.804 and 0.874, respectively. The sensitivity and specificity of SMRP combined with the CYFRA 21-1/CEA ratio were 93.8% and 64.9%, respectively. The sensitivity of the combination of SMRP, the CYFRA 21-1/CEA ratio, and the presence of Leung's criteria (a chest CT finding that is suggestive of malignant pleural disease) was 93.8%. In conclusion, the combined PE biomarkers had a high sensitivity for diagnosing MPM, although the addition of chest CT findings did not improve the sensitivity of SMRP combined with the CYFRA 21-1/CEA ratio. Combination of these biomarkers helped to rule out MPM effectively among patients at high risk of suffering MPM and would be valuable especially for old frail patients who have difficulty in undergoing invasive procedures such as thoracoscopy.
[Mh] Termos MeSH primário: Neoplasias Pulmonares/diagnóstico
Mesotelioma/diagnóstico
Derrame Pleural/metabolismo
Neoplasias Pleurais/diagnóstico
[Mh] Termos MeSH secundário: Idoso
Antígenos de Neoplasias/metabolismo
Feminino
Seres Humanos
Queratina-19/metabolismo
Neoplasias Pulmonares/diagnóstico por imagem
Neoplasias Pulmonares/patologia
Masculino
Mesotelioma/diagnóstico por imagem
Mesotelioma/patologia
Meia-Idade
Derrame Pleural/diagnóstico por imagem
Neoplasias Pleurais/diagnóstico por imagem
Neoplasias Pleurais/patologia
Estudos Retrospectivos
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Keratin-19); 0 (antigen CYFRA21.1)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171003
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0185850


  6 / 1396 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28910822
[Au] Autor:Osako T; Iwase T; Ushijima M; Yonekura R; Ohno S; Akiyama F
[Ad] Endereço:Department of Pathology, The Cancer Institute Hospital, The Japanese Foundation for Cancer Research, Tokyo, Japan.
[Ti] Título:A new molecular-based lymph node staging classification determines the prognosis of breast cancer patients.
[So] Source:Br J Cancer;117(10):1470-1477, 2017 Nov 07.
[Is] ISSN:1532-1827
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The one-step nucleic acid amplification (OSNA) assay is a novel molecular method that can detect metastasis in a whole lymph node based on cytokeratin 19 mRNA copy number. This cohort study aimed to establish an OSNA-based nodal staging (pN(mol)) classification for breast cancer. METHODS: The cohort consisted of 1039 breast cancer patients who underwent sentinel node (SN) biopsy using the OSNA assay. Cutoff value of the SN tumour burden stratifying distant disease-free survival (DDFS) was determined, and predictive factors for DDFS and breast cancer-specific survival (BCSS) were investigated. pN(mol) classification of the SN status was defined as: pN0(mol)(sn), SN negative; pN1mi(mol)(sn), SN positive and tumour burden
[Mh] Termos MeSH primário: Biomarcadores Tumorais/análise
Neoplasias da Mama/patologia
Metástase Linfática/diagnóstico
Estadiamento de Neoplasias/métodos
Técnicas de Amplificação de Ácido Nucleico/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias da Mama/mortalidade
Estudos de Coortes
Intervalo Livre de Doença
Feminino
Dosagem de Genes
Seres Humanos
Queratina-19/análise
Queratina-19/genética
Metástase Linfática/patologia
Meia-Idade
Prognóstico
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Keratin-19)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170915
[St] Status:MEDLINE
[do] DOI:10.1038/bjc.2017.311


  7 / 1396 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28892096
[Au] Autor:Loarca L; De Assuncao TM; Jalan-Sakrikar N; Bronk S; Krishnan A; Huang B; Morton L; Trussoni C; Bonilla LM; Krueger E; O'Hara S; Splinter P; Shi G; Pisarello MJL; Gores GJ; Huebert RC; LaRusso NF
[Ad] Endereço:Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
[Ti] Título:Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis.
[So] Source:Lab Invest;97(11):1385-1396, 2017 Nov.
[Is] ISSN:1530-0307
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Primary sclerosing cholangitis (PSC) is an incurable, fibroinflammatory biliary disease for which there is no effective pharmacotherapy. We recently reported cholangiocyte senescence as an important phenotype in PSC while others showed that portal macrophages accumulate in PSC. Unfortunately, our ability to explore cholangiocyte senescence and macrophage accumulation has been hampered by limited in vitro models. Thus, our aim was to develop and characterize a three-dimensional (3D) model of normal and diseased bile ducts (cholangioids) starting with normal human cholangiocytes (NHC), senescent NHC (NHC-sen), and cholangiocytes from PSC patients. In 3D culture, NHCs formed spheroids of ~5000 cells with a central lumen of ~150 µm. By confocal microscopy and western blot, cholangioids retained expression of cholangiocyte proteins (cytokeratin 7/19) and markers of epithelial polarity (secretin receptor and GM130). Cholangioids are functionally active, and upon secretin stimulation, luminal size increased by ~80%. Cholangioids exposed to hydrogen peroxide exhibited cellular senescence and the senescence-associated secretory phenotype (SASP; increased IL-6, p21, SA-ß-Gal, yH2A.x and p16 expression). Furthermore, cholangioids derived from NHC-sen or PSC patients were smaller and had slower growth than the controls. When co-cultured with THP-1 macrophages, the number of macrophages associated with NHC-sen or PSC cholangioids was five- to seven-fold greater compared to co-culture with non-senescent NHC. We observed that NHC-sen and PSC cholangioids release greater number of extracellular vesicles (EVs) compared to controls. Moreover, conditioned media from NHC-sen cholangioids resulted in an ~2-fold increase in macrophage migration. In summary, we developed a method to generate normal and diseased cholangioids, characterized them morphologically and functionally, showed that they can be induced to senescence and SASP, and demonstrated both EV release and macrophage attraction. This novel model mimics several features of PSC, and thus will be useful for studying the pathogenesis of PSC and potentially identifying new therapeutic targets.
[Mh] Termos MeSH primário: Ductos Biliares/patologia
Colangite Esclerosante/patologia
Esferoides Celulares/patologia
[Mh] Termos MeSH secundário: Autoantígenos/metabolismo
Ductos Biliares/efeitos dos fármacos
Ductos Biliares/metabolismo
Ductos Biliares/ultraestrutura
Biomarcadores/metabolismo
Linhagem Celular
Células Cultivadas
Senescência Celular/efeitos dos fármacos
Colangite Esclerosante/imunologia
Colangite Esclerosante/metabolismo
Técnicas de Cocultura
Meios de Cultivo Condicionados
Vesículas Extracelulares/efeitos dos fármacos
Vesículas Extracelulares/metabolismo
Vesículas Extracelulares/patologia
Vesículas Extracelulares/ultraestrutura
Regulação da Expressão Gênica/efeitos dos fármacos
Seres Humanos
Peróxido de Hidrogênio/toxicidade
Queratina-19/metabolismo
Queratina-7/metabolismo
Ativação de Macrófagos
Macrófagos/citologia
Macrófagos/imunologia
Proteínas de Membrana/metabolismo
Microscopia Eletrônica de Transmissão
Corpos Multivesiculares/efeitos dos fármacos
Corpos Multivesiculares/metabolismo
Corpos Multivesiculares/patologia
Corpos Multivesiculares/ultraestrutura
Oxidantes/toxicidade
Receptores Acoplados a Proteínas-G/metabolismo
Receptores dos Hormônios Gastrointestinais/metabolismo
Esferoides Celulares/efeitos dos fármacos
Esferoides Celulares/metabolismo
Esferoides Celulares/ultraestrutura
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Autoantigens); 0 (Biomarkers); 0 (Culture Media, Conditioned); 0 (Golgin subfamily A member 2); 0 (KRT7 protein, human); 0 (Keratin-19); 0 (Keratin-7); 0 (Membrane Proteins); 0 (Oxidants); 0 (Receptors, G-Protein-Coupled); 0 (Receptors, Gastrointestinal Hormone); 0 (secretin receptor); BBX060AN9V (Hydrogen Peroxide)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170912
[St] Status:MEDLINE
[do] DOI:10.1038/labinvest.2017.63


  8 / 1396 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28870944
[Au] Autor:Sone K; Oguri T; Ito K; Kitamura Y; Inoue Y; Takeuchi A; Fukuda S; Takakuwa O; Maeno K; Asano T; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
[Ad] Endereço:Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
[Ti] Título:Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients.
[So] Source:Anticancer Res;37(9):5125-5131, 2017 09.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: The aim of the present study was to determine the clinical value of tumor marker levels for previously treated NSCLC patients. PATIENTS AND METHODS: We retrospectively screened 113 previously treated patients with advanced NSCLC who were treated with docetaxel monotherapy regarding the pretreatment serum level of cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA). RESULTS: The thirty-two patients with normal CYFRA21-1 levels and high CEA levels had a significantly higher response rate than the other 81 patients (25% vs. 8.6%, p=0.031). The former group showed statistically longer progression-free survival (PFS) and overall survival (OS) than the latter group (median PFS, 180 vs. 59 days, p<0.001; median OS, 579 vs. 255 days, p=0.002). In multivariate analysis, tumor marker levels had a significant impact on PFS and OS. CONCLUSION: Combination of the two tumor markers is a predictive and prognostic marker of docetaxel monotherapy for previously treated NSCLC patients.
[Mh] Termos MeSH primário: Antígenos de Neoplasias/sangue
Antineoplásicos/uso terapêutico
Antígeno Carcinoembrionário/sangue
Carcinoma Pulmonar de Células não Pequenas/sangue
Queratina-19/sangue
Neoplasias Pulmonares/tratamento farmacológico
Taxoides/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais/sangue
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Intervalo Livre de Doença
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Neoplasias Pulmonares/sangue
Masculino
Meia-Idade
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); 0 (Carcinoembryonic Antigen); 0 (Keratin-19); 0 (Taxoids); 0 (antigen CYFRA21.1); 15H5577CQD (docetaxel)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE


  9 / 1396 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28797030
[Au] Autor:Shi F; Zhang Q; Liang Z; Zhang M; Liu X
[Ad] Endereço:Department of Epidemiology and Statistics, School of Public Health, Jilin University, No. 1163, Xinmin Avenue, Changchun 130021, China.
[Ti] Título:One-step nucleic acid amplification assay is an accurate technique for sentinel lymph node biopsy of breast cancer patients: a meta-analysis.
[So] Source:Br J Cancer;117(8):1185-1191, 2017 Oct 10.
[Is] ISSN:1532-1827
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: To estimate the accuracy of one-step nucleic acid amplification (OSNA) assay as an intra-operative sentinel lymph node biopsy (SLNB) for sentinel lymph node (SLN) metastasis in breast cancer. METHODS: PubMed, Cochrane Library and Web of Science databases were searched by two independent reviewers to retrieve literature with per-patient analysis. The deadline was up until December 2016. A meta-analysis was performed using STATA, Meta-Disc, and Revman software. A random-effects model was used and subgroup analysis was carried out to identify possible sources of heterogeneity. RESULTS: According to the inclusion criteria, 2833 patients from 12 studies were included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and the area under the sROC curve (AUC) for detecting SLN metastasis were 0.87 (95% CI 0.81-0.91), 0.92 (95% CI 0.86-0.95), 10.65 (95% CI 6.18-18.34), 0.14 (95% CI 0.10-0.20), 75.08 (95% CI 37.77-149.22) and 0.94 (95% CI 0.91-0.95), respectively. CONCLUSIONS: The present study adds the evidence that OSNA assay is an accurate molecular diagnostic tool for intra-operatively detecting SLN metastasis in breast cancer. One-step nucleic acid amplification assay might be introduced into clinical usage for replacing traditional intro-operative diagnostic methods of SLNB.
[Mh] Termos MeSH primário: Neoplasias da Mama/metabolismo
Carcinoma/metabolismo
Queratina-19/genética
RNA Mensageiro/metabolismo
Biópsia de Linfonodo Sentinela/métodos
Linfonodo Sentinela/metabolismo
[Mh] Termos MeSH secundário: Axila
Neoplasias da Mama/patologia
Carcinoma/patologia
Feminino
Seres Humanos
Excisão de Linfonodo
Estadiamento de Neoplasias
Técnicas de Amplificação de Ácido Nucleico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Keratin-19); 0 (RNA, Messenger)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170811
[St] Status:MEDLINE
[do] DOI:10.1038/bjc.2017.262


  10 / 1396 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28671689
[Au] Autor:Sampaziotis F; Justin AW; Tysoe OC; Sawiak S; Godfrey EM; Upponi SS; Gieseck RL; de Brito MC; Berntsen NL; Gómez-Vázquez MJ; Ortmann D; Yiangou L; Ross A; Bargehr J; Bertero A; Zonneveld MCF; Pedersen MT; Pawlowski M; Valestrand L; Madrigal P; Georgakopoulos N; Pirmadjid N; Skeldon GM; Casey J; Shu W; Materek PM; Snijders KE; Brown SE; Rimland CA; Simonic I; Davies SE; Jensen KB; Zilbauer M; Gelson WTH; Alexander GJ; Sinha S; Hannan NRF; Wynn TA; Karlsen TH; Melum E; Markaki AE; Saeb-Parsy K; Vallier L
[Ad] Endereço:Wellcome Trust-Medical Research Council Stem Cell Institute, Cambridge Stem Cell Institute, Anne McLaren Laboratory, University of Cambridge, Cambridge, UK.
[Ti] Título:Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids.
[So] Source:Nat Med;23(8):954-963, 2017 Aug.
[Is] ISSN:1546-170X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The treatment of common bile duct (CBD) disorders, such as biliary atresia or ischemic strictures, is restricted by the lack of biliary tissue from healthy donors suitable for surgical reconstruction. Here we report a new method for the isolation and propagation of human cholangiocytes from the extrahepatic biliary tree in the form of extrahepatic cholangiocyte organoids (ECOs) for regenerative medicine applications. The resulting ECOs closely resemble primary cholangiocytes in terms of their transcriptomic profile and functional properties. We explore the regenerative potential of these organoids in vivo and demonstrate that ECOs self-organize into bile duct-like tubes expressing biliary markers following transplantation under the kidney capsule of immunocompromised mice. In addition, when seeded on biodegradable scaffolds, ECOs form tissue-like structures retaining biliary characteristics. The resulting bioengineered tissue can reconstruct the gallbladder wall and repair the biliary epithelium following transplantation into a mouse model of injury. Furthermore, bioengineered artificial ducts can replace the native CBD, with no evidence of cholestasis or occlusion of the lumen. In conclusion, ECOs can successfully reconstruct the biliary tree, providing proof of principle for organ regeneration using human primary cholangiocytes expanded in vitro.
[Mh] Termos MeSH primário: Ductos Biliares Extra-Hepáticos/fisiologia
Células Epiteliais/citologia
Vesícula Biliar/fisiologia
Organoides/fisiologia
Regeneração/fisiologia
Engenharia Tecidual/métodos
[Mh] Termos MeSH secundário: Animais
Ductos Biliares Extra-Hepáticos/citologia
Ductos Biliares Extra-Hepáticos/lesões
Sistema Biliar/citologia
Sistema Biliar/lesões
Sistema Biliar/fisiologia
Transplante de Células
Regulador de Condutância Transmembrana em Fibrose Cística/metabolismo
Células Epiteliais/efeitos dos fármacos
Células Epiteliais/metabolismo
Vesícula Biliar/lesões
Seres Humanos
Técnicas In Vitro
Queratina-19/metabolismo
Queratina-7/metabolismo
Camundongos
Organoides/citologia
Organoides/efeitos dos fármacos
Organoides/metabolismo
Secretina/farmacologia
Somatostatina/farmacologia
Tecidos Suporte
gama-Glutamiltransferase/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; VIDEO-AUDIO MEDIA
[Nm] Nome de substância:
0 (Keratin-19); 0 (Keratin-7); 126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator); 1393-25-5 (Secretin); 51110-01-1 (Somatostatin); EC 2.3.2.2 (gamma-Glutamyltransferase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171114
[Lr] Data última revisão:
171114
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170704
[St] Status:MEDLINE
[do] DOI:10.1038/nm.4360



página 1 de 140 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde